EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

LncRNA SLNCR phenocopies the E2F1 DNA binding site to promote melanoma progression

Kushani Shah, Eleni Anastasakou, Leinal Sejour, Yufei Wang, Leon Wert-Lamas, Christopher Rauchet, Sabine Studer, Simon Goller, Robert J Distel, Wayne Marasco, Lalith Perera, Ioannis S Vlachos und 1 weitere

Cell Reports · 2025

DOI: 10.1016/j.celrep.2025.115608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Kushani Shah und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, …. Hauptthemen laut MEDLINE: E2F1 Transcription Factor, RNA, Long Noncoding, Melanoma, Disease Progression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

E2F1 Transcription FactorRNA, Long NoncodingMelanomaDisease ProgressionDNABinding SitesAnimalsHumansMiceMolecular Dynamics SimulationCell Line, TumorCell ProliferationCell MovementProtein Binding

Stichwörter der Autor:innen

CP: CancerCP: GenomicsE2F1Long non-coding RNARNA-EMSASLNCRmelanomamolecular dynamics simulationstranscription factor-RNA binding

Substanzen

E2F1 Transcription FactorRNA, Long NoncodingE2F1 protein, humanDNA

Autor:innen und Institutionen

  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02141…
  • Broad Institute of Harvard and MIT, Cambridge, MA 02141, USA; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Genome Integrity and Structural Biology Laboratory, NIEHS, NIH, Durham, NC 27709, USA.
  • Broad Institute of Harvard and MIT, Cambridge, MA 02141, USA; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA; Spatial Technologies Unit, Harvard Medical Scho…

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • NHLBI NIH HHS
  • Intramural NIH HHS
  • National Cancer Institute Division of Cancer Epidemiology and Genetics
  • National Institute of Diabetes and Digestive and Kidney Diseases Division of Diabetes Endocrinology and Metabolic Diseases
  • National Institute of Environmental Health Sciences
  • Swiss National Science Foundation

Zitieren

APA

Shah, K., Anastasakou, E., Sejour, L., Wang, Y., Wert-Lamas, L., Rauchet, C., Studer, S., Goller, S., Distel, R. J., Marasco, W., Perera, L., Vlachos, I. S., & Novina, C. D. (2025). LncRNA SLNCR phenocopies the E2F1 DNA binding site to promote melanoma progression. Cell Reports. https://doi.org/10.1016/j.celrep.2025.115608

Vancouver

Shah K, Anastasakou E, Sejour L, Wang Y, Wert-Lamas L, Rauchet C, et al. LncRNA SLNCR phenocopies the E2F1 DNA binding site to promote melanoma progression. Cell Reports. 2025. doi:10.1016/j.celrep.2025.115608

BibTeX
@article{Shah2025,
  author = {Shah, Kushani and Anastasakou, Eleni and Sejour, Leinal and Wang, Yufei and Wert-Lamas, Leon and Rauchet, Christopher and Studer, Sabine and Goller, Simon and Distel, Robert J and Marasco, Wayne and Perera, Lalith and Vlachos, Ioannis S and Novina, Carl D},
  title = {LncRNA SLNCR phenocopies the E2F1 DNA binding site to promote melanoma progression},
  journal = {Cell Reports},
  year = {2025},
  doi = {10.1016/j.celrep.2025.115608}
}
Kostenlos starten →